Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Research

Post-Stroke-Brain-Stimulation-2
July 8, 2019/Neurosciences/Research

Trial Explores Combination of Contralesional Brain Stimulation and Neuromuscular Stimulation for Post-Stroke Upper Limb Paresis

NIH-funded clinical study pairs up two innovative techniques

19-NEU-462-DeSilva-Leverenz-Alzheimers-CQD-650×450

Probing the Innate Immune System’s Role in Alzheimer’s Disease

Interdisciplinary research aims to glean insights for therapeutic translation

19-NEU-319-Caren-Treadmill-MS-650×450
June 4, 2019/Neurosciences/Research

Virtual Reality Platform’s Dynamic Approach to Physical Therapy Yields Benefits in MS

Preliminary study finds improved gait and balance vs. traditional PT

Walking in snow
May 30, 2019/Neurosciences/Research

Can Exercise Alter Parkinson Disease Progression? NIH Award Launches First Long-Term Study to Find Out

Study to assess effects of 12 months of home-based cycling

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

19-NEU-321-excessive-sleepiness-650×450

Solriamfetol Demonstrates Safety, Efficacy for Wakefulness in 1-Year Extension Trial

New drug for adults with OSA or narcolepsy expected to launch soon

19-NEU-320-RNS-neurostimulation-650×450

Seizure Reductions with Responsive Neurostimulation Grow Over Time, Long-Term Study Shows

75% median reduction in seizures observed over 9 years of treatment

19-NEU-322-immunosuppression-650×450
May 7, 2019/Cancer

Degree of Immunosuppression Predicts Glioblastoma Prognosis, Temozolomide Studies Suggest

Experience to date highlights need for immunotherapy focus

19-NEU-325-deep-gray-matter_650x450

Assessing Deep Gray Matter Atrophy as a Predictor of Clinical Disability in MS

Study finds strong association between brain/thalamic volume and T2 lesion volume

19-NEU-326-multiple-sclerosis-650×450

Highly Effective Therapies Used in Only a Minority of Relapsing MS Cases, Study Finds

Prescribing practices analyzed over 12+ years across 10 sites

19-NEU-324-SPRINT-MS-650×450

SPRINT-MS Subanalysis Shows Greater Effect for Ibudilast in Primary Vs. Secondary Progressive MS

Findings may be due to faster atrophy progression in primary progressive MS

BackPage 9 of 17Next

Advertisement

Ad